Delgocitinib is a Janus kinase (JAK) inhibitor used to treat atopic dermatitis. Information on the specific synthesis process of delgocitinib's patent is not readily available in the provided context.
When does the delgocitinib patent expire?
The patent expiration date for delgocitinib varies by region and specific patent. DrugPatentWatch.com tracks patent exclusivity for pharmaceuticals. For instance, the main delgocitinib patent in the United States is set to expire around 2031 [1]. However, additional patents may extend market exclusivity.
Who manufactures delgocitinib?
Delgocitinib is developed and manufactured by Torii Pharmaceutical Co., Ltd. and its partner, Pfizer Inc. [2].
How does delgocitinib work?
Delgocitinib works by inhibiting JAK enzymes, which play a role in the signaling pathways of various cytokines involved in inflammation and immune responses. By blocking these pathways, delgocitinib helps to reduce the inflammation associated with atopic dermatitis [3].
What is the efficacy of delgocitinib for atopic dermatitis?
Clinical trials have shown delgocitinib to be effective in improving the symptoms of atopic dermatitis. For example, a Phase 3 study demonstrated significant improvements in Eczema Area and Severity Index (EASI) scores and itch reduction in patients treated with delgocitinib [2][3].
What are the potential side effects of delgocitinib?
Common side effects reported with delgocitinib include nasopharyngitis, upper respiratory tract infection, dermatitis, and acne [3].
Are there alternative treatments for atopic dermatitis?
Yes, several other treatments are available for atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors, and other systemic therapies, including other JAK inhibitors.
What is the regulatory status of delgocitinib?
Delgocitinib has been approved in Japan for the treatment of atopic dermatitis. Regulatory submissions in other regions are ongoing [2].
Can biosimilars be developed for delgocitinib?
The development of biosimilars for delgocitinib will depend on patent expiry and the specific regulatory pathways in different countries. Biosimilar development typically occurs after primary patents expire.
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-torii-pharmaceutical-announce-positive-top-line-results-for-phase-3-study-of-delgocitinib-cream-in-japanese-patients-with-atopic-dermatitis
[3] https://www.jaad.org/article/S0190-9622(23)00178-0/fulltext